| __timestamp | Agios Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 15823000 |
| Thursday, January 1, 2015 | 141827000 | 17026000 |
| Friday, January 1, 2016 | 220163000 | 15941000 |
| Sunday, January 1, 2017 | 292681000 | 18938000 |
| Monday, January 1, 2018 | 341324000 | 58124000 |
| Tuesday, January 1, 2019 | 410894000 | 83837000 |
| Wednesday, January 1, 2020 | 367470000 | 35882000 |
| Friday, January 1, 2021 | 256973000 | 64542000 |
| Saturday, January 1, 2022 | 279910000 | 67995000 |
| Sunday, January 1, 2023 | 288903000 | 80118000 |
| Monday, January 1, 2024 | 301286000 |
Data in motion
In the competitive landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Agios Pharmaceuticals, Inc. has consistently outpaced CymaBay Therapeutics, Inc. in R&D investment. From 2014 to 2023, Agios's R&D expenses grew by approximately 188%, peaking in 2019. In contrast, CymaBay's R&D spending increased by about 406% during the same period, albeit from a much smaller base. This disparity highlights Agios's robust financial commitment to innovation, with annual R&D expenses often exceeding CymaBay's by more than 300%. However, CymaBay's rapid growth in R&D spending, particularly between 2018 and 2023, underscores its emerging focus on innovation. As the biotech industry evolves, these spending patterns may influence future breakthroughs and market dynamics.
Comparing Innovation Spending: Novo Nordisk A/S and Agios Pharmaceuticals, Inc.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Takeda Pharmaceutical Company Limited and Agios Pharmaceuticals, Inc.
Comparing Innovation Spending: Bio-Techne Corporation and Agios Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
PTC Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Vericel Corporation and Agios Pharmaceuticals, Inc.
R&D Insights: How Arrowhead Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.